Get started
Author

Mahmoud El‐Shemerly

Observed names: M. El Shemerly, M. El-Shemerly, Mahmoud EL Shemerly, Mahmoud El Shemerly, Mahmoud El-Shemerly, Mahmoud Y. El-Shemerly, Mahmoud Y. M. El-Shemerly, Mahmoud Y.M. El-Shemerly, Mahmoud Y.M.El Shemerly
ORCID: 0000-0001-8914-7970
Observed ORCID: 0000-0001-8914-7970
OpenAlex ID: A5060594687
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells
2018 · Don Benjamin, Dimitri Robay, et al. · Cell Reports · 433
PDF
DNA end resection by CtIP and exonuclease 1 prevents genomic instability
2010 · Wassim Eid, Martin Steger, et al. · EMBO Reports · 142
PDF
Aurora-A site specificity: a study with synthetic peptide substrates
2005 · Stefano Ferrari, Oriano Marin, et al. · Biochemical Journal · 113
Syrosingopine sensitizes cancer cells to killing by metformin
2016 · Don Benjamin, Marco Colombi, et al. · Science Advances · 91
PDF
ATR-dependent pathways control hEXO1 stability in response to stalled forks
2007 · Mahmoud El-Shemerly, Daniel Hess, et al. · Nucleic Acids Research · 83
PDF
12-O-Tetradecanoylphorbol-13acetate Activates the Ras/ Extracellular Signal-regulated Kinase (ERK) Signaling Pathway Upstream of SOS Involving Serine Phosphorylation of Shc in NIH3T3 Cells
1997 · Mahmoud Y.M. El-Shemerly, Daniel Besser, et al. · Journal of Biological Chemistry · 70
Degradation of Human Exonuclease 1b upon DNA Synthesis Inhibition
2005 · Mahmoud El-Shemerly, Pavel Janscak, et al. · Cancer Research · 60
PDF
Mismatch Repair Status and the Response of Human Cells to Cisplatin
2007 · Elisabetta Pani, Lovorka Stojic, et al. · Cell Cycle · 49
PDF
Serine/Threonine Phosphorylation of ShcA
2002 · Amir Faisal, Mahmoud El-Shemerly, et al. · Journal of Biological Chemistry · 47
PDF
Activation and Nuclear Translocation of Mitogen-activated Protein Kinases by Polyomavirus Middle-T or Serum Depend on Phosphatidylinositol 3-Kinase
1995 · Marc Urich, Mahmoud Y.M.El Shemerly, et al. · Journal of Biological Chemistry · 46
14-3-3 checkpoint regulatory proteins interact specifically with DNA repair protein human exonuclease 1 (hEXO1) via a semi-conserved motif
2012 · Sofie Dabros Andersen, Guido Keijzers, et al. · DNA repair · 35
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma
2021 · Stephan Braun, Paul McSheehy, et al. · Expert Opinion on Investigational Drugs · 20
The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo
2022 · Paul M.J. McSheehy, Nicole Forster-Gross, et al. · Anti-Cancer Drugs · 7
Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer
2019 · Paul McSheehy, Felix Bachmann, et al. · Molecular Cancer Therapeutics · 6
Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models
2020 · P. Mcsheehy, J. Boult, et al. · European Journal of Cancer · 4
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models
2022 · Mahmoud El Shemerly, Elisa Zanini, et al. · Anti-Cancer Drugs · 3
Abstract 5501: Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model
2022 · Mahmoud EL Shemerly, Laurenz Kellenberger, et al. · Cancer Research · 3
Discovery and optimization of oxidative phosphorylation inhibitors from a phenotypic screen
2025 · Mahmoud El Shemerly, Florian Richalet, et al. · Anti-Cancer Drugs · 2
The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR.
2020 · Paul McSheehy, Felix Bachmann, et al. · Journal of Clinical Oncology · 2
Exonuclease-1 interacts with the transcriptional co-repressor KAP1
2016 · Mahmoud El-Shemerly, Wassim Eid, et al. · Matters · 1
Supplementary Figure 1 from Degradation of Human Exonuclease 1b upon DNA Synthesis Inhibition
2023 · Mahmoud El-Shemerly, Pavel Janscak, et al.
PDF
Data from Degradation of Human Exonuclease 1b upon DNA Synthesis Inhibition
2023 · Mahmoud El-Shemerly, Pavel Janscak, et al.
Derazantinib, an inhibitor of fibroblast growth factor receptors 1–3, increases the efficacy of paclitaxel combined with a VEGFR2-antibody in murine syngeneic tumor models
2022 · P. Mcsheehy, M. El-Shemerly, et al. · European Journal of Cancer
PDF
Abstract P238: Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, synergises with paclitaxel in pre-clinical gastric tumor models
2021 · Paul M. McSheehy, Mahmoud El Shemerly, et al. · Molecular Cancer Therapeutics
Works count: 24
Citation count: 1,217
H-index: 12
I10-index: 12
Year
Topic
Type